• Tracked macroeconomic and market data, supported updates of weekly and monthly reports, and advised on asset allocation; assisted in fund recommendations, achieving an average annual return of over 10% for all selected funds• Conducted asset allocation research using Bloomberg and Macrobond, creating over 200 charts across various sectors including equities, bonds, cryptocurrencies, and commodities, significantly boosting departmental efficiency

• Wrote an initial report for GenrixBio (688443.SH), analyzing IL-17A and IL-4Rα targets in autoimmune diseases, market dynamics, evaluating the rabies bispecific antibody market, and developed a DCF valuation model• Authored an in-depth report on Keymed Bioscience (02162.HK) to explore its differentiated pipeline and the potential of its key product, Stapokibart, and TCE bispecific antibodies• Supported analysts by updating innovative drug research data from 2023 AACR and ASCO conferences; participated in 10+ conference calls and 2 strategy sessions, producing over 20 meeting summaries

• Supported the Investment Director in ProteLight Pharma’ Series D financing, conducted interviews with key industry stakeholders, and prepared 27 summaries; assisted in writing a 24-page project report focusing on target analysis, industry overview, deal structure, valuation, and ROI• Researched the oligonucleotide drug sector, covering market trends, clinical developments, and supply chain dynamics; analyzed R&D challenges and devised investment strategies, identifying 5 future targets in a streamlined 40-page presentation